Mutual of America Capital Management LLC Trims Stake in Illumina, Inc. $ILMN

Mutual of America Capital Management LLC trimmed its holdings in Illumina, Inc. (NASDAQ:ILMN) by 3.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 78,723 shares of the life sciences company’s stock after selling 2,802 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Illumina were worth $7,511,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of ILMN. Carmel Capital Partners LLC boosted its stake in shares of Illumina by 37.0% during the second quarter. Carmel Capital Partners LLC now owns 3,908 shares of the life sciences company’s stock worth $373,000 after buying an additional 1,055 shares during the period. Sage Private Wealth Group LLC raised its stake in Illumina by 79.5% during the 2nd quarter. Sage Private Wealth Group LLC now owns 6,649 shares of the life sciences company’s stock valued at $634,000 after acquiring an additional 2,945 shares during the last quarter. Nordea Investment Management AB lifted its position in Illumina by 14.2% during the 2nd quarter. Nordea Investment Management AB now owns 13,138 shares of the life sciences company’s stock worth $1,265,000 after acquiring an additional 1,633 shares during the period. WCM Investment Management LLC grew its stake in shares of Illumina by 5.9% in the 2nd quarter. WCM Investment Management LLC now owns 4,426,471 shares of the life sciences company’s stock valued at $419,585,000 after purchasing an additional 247,460 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB increased its holdings in shares of Illumina by 36.6% in the second quarter. Wilmington Savings Fund Society FSB now owns 8,194 shares of the life sciences company’s stock valued at $782,000 after purchasing an additional 2,194 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Price Performance

Illumina stock opened at $99.50 on Tuesday. The stock has a market capitalization of $15.29 billion, a P/E ratio of 12.59, a P/E/G ratio of 2.31 and a beta of 1.40. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. The firm’s 50-day moving average is $98.22 and its two-hundred day moving average is $91.01.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The company had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the previous year, the firm posted $0.36 EPS. Illumina’s revenue was down 4.8% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Equities analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on ILMN. Stephens set a $110.00 price target on Illumina and gave the stock an “overweight” rating in a report on Monday, August 4th. Citigroup cut shares of Illumina from a “hold” rating to a “strong sell” rating and reduced their target price for the stock from $85.00 to $80.00 in a research note on Wednesday, July 9th. Royal Bank Of Canada set a $124.00 target price on shares of Illumina in a report on Tuesday, September 2nd. Daiwa Capital Markets cut shares of Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 price target for the company. in a report on Tuesday, August 12th. Finally, Evercore ISI lowered their price objective on Illumina from $135.00 to $132.00 and set an “outperform” rating on the stock in a report on Tuesday, October 7th. Five research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $115.25.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.